Cuu Long Pharmaceutical JSC
Cuu Long Pharmaceutical Joint Stock Company produces drugs, chemicals, and medicines in Vietnam. It offers antiallergy, pain reliever and fever reducer, antibiotic, anti-inflammatory, antiviral, cardiovascular, corticosteroid, cough, dermatology, digestive, nervous system, musculoskeletal, and vitamin and mineral medicines, as well as capsules and medical equipment. The company is also involved i… Read more
Cuu Long Pharmaceutical JSC (DCL) - Net Assets
Latest net assets as of : ₫- VND
Based on the latest financial reports, Cuu Long Pharmaceutical JSC (DCL) has net assets worth ₫- VND as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₫-) and total liabilities (₫-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₫- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cuu Long Pharmaceutical JSC - Net Assets Trend (None–None)
This chart illustrates how Cuu Long Pharmaceutical JSC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cuu Long Pharmaceutical JSC (None–None)
The table below shows the annual net assets of Cuu Long Pharmaceutical JSC from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Cuu Long Pharmaceutical JSC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Cuu Long Pharmaceutical JSC Competitors by Market Cap
The table below lists competitors of Cuu Long Pharmaceutical JSC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Goldenstone Acquisition Limited Warrants
NASDAQ:GDSTW
|
$20.98K |
|
Med Life S.A.
F:O0C
|
$20.98K |
|
E-Elements Technology Co., Ltd.
TWO:6842
|
$21.01K |
|
Mari Petroleum Company Ltd
KAR:MARI
|
$21.01K |
|
Greenyn Biotechnology Co., Ltd
TWO:6846
|
$20.97K |
|
Matba Rofex SA
BA:MTR
|
$20.96K |
|
Regal Investment Fund
AU:RF1
|
$20.94K |
|
SRNA3F
SA:SRNA3F
|
$20.94K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cuu Long Pharmaceutical JSC's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Cuu Long Pharmaceutical JSC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Cuu Long Pharmaceutical JSC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Cuu Long Pharmaceutical JSC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,979,636,361,615
- Average return on equity (ROE) among peers: 16.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cuu Long Pharmaceutical JSC (DCL) | ₫- | N/A | N/A | $20.97K |
| Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) | $1.66 Trillion | 16.57% | 0.36x | $183.29 Million |
| DHG Pharmaceutical JSC (DHG) | $3.57 Trillion | 20.74% | 0.25x | $29.78 Million |
| DOMESCO Medical Import Export JSC (DMC) | $1.25 Trillion | 18.58% | 0.22x | $21.40K |
| Imexpharm Corp (IMP) | $1.73 Trillion | 12.12% | 0.21x | $119.65 Million |
| Traphaco JSC (TRA) | $1.69 Trillion | 14.81% | 0.39x | $27.57 Million |